ClinicalTrials.gg
TerminatedNCT03841448Updated Aug 9, 2024Results posted

A Study of Cemdisiran in Adults With Immunoglobulin A Nephropathy (IgAN)

A Phase 2 interventional study of Placebo and Cemdisiran in IgA Nephropathy (IgAN), Berger Disease and Glomerulonephritis, IgA, sponsored by Alnylam Pharmaceuticals. Terminated at 17 sites in 9 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2024-08-09.

Sponsored by Alnylam Pharmaceuticals · Phase 2, Interventional, and Treatment

Why this study was terminated
Study was terminated early having identified clinically meaningful magnitude of proteinuria reduction due to cemdisiran (study goal). Participants completed DBT period\&were in OLE period. Sponsor had no concerns with safety\&integrity of participants.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
31
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 22 studies in Glomerulonephritis, IGA with a site in Canada — 4 open to participants now, 11 under way, 10 of them phase 3. Glomerulonephritis, IGA · Canada.

Enrollment
19th of 21
31 · median 383
Started
2019
with 1 other
Phase 2
5 of 22
none open now
Registered
5th of 22
by date
Lead sponsor
1 of 22
Alnylam Pharmaceuticals

Among the 22 studies in Glomerulonephritis, IGA with a site in Canada, this one is the 19th largest by enrollment of the 21 interventional ones that give a count, is one of 2 that started in 2019, is one of 5 in phase 2, and was the 5th registered.

Glomerulonephritis, IGA

276 studies on the registry are indexed under Glomerulonephritis, IGA; 108 are open to participants now.

Browse Glomerulonephritis, IGA studies →

Open to participants now

4 of the 22 studies in Glomerulonephritis, IGA with a site in Canada are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →

Who these studies take

Of the 68 Glomerulonephritis, IGA studies recruiting now, 39 (57%) set no upper age limit and 24 (35%) stop at 75 or younger; 21 take children under 18; 5 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 22 studies in Glomerulonephritis, IGA with a site in Canada, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the effect of cemdisiran on proteinuria in adults with immunoglobulin A nephropathy (IgAN), who excrete >1 gram (gm) of protein per day despite standard of care, which includes treatment with angiotensin-converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARB). These participants are at high risk for progression of kidney disease, which can result in end-stage renal failure.

03

Conditions studied

  • IgA Nephropathy (IgAN)
  • Berger Disease
  • Glomerulonephritis, IgA
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosed with primary IgAN
  • Currently being treated for IgAN with stable, optimal therapy, including an ACE inhibitor or ARB.
  • Has urine protein greater than or equal to 1 gram/24-hour
  • Has hematuria (blood cells present in urine)

Exclusion criteria

Exclusion Criteria:

  • Has renal disease other than IgAN
  • Has a diagnosis of rapidly progressive glomerulonephritis
  • Has a diagnosis of Henoch-Schonlein Purpura (IgA Vasculitis)
  • Has poor kidney function with estimated (eGFR) \<30 milliliters per minute per 1.73 meters square (mL/min/1.73 m\^2)
  • Has known (HIV) infection, virus (HCV) infection or virus (HBV) infection
  • Has on-going high blood pressure
  • Treated with systemic for more than 7 days, or other agents in the past 6 months
  • Received an organ transplant
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
31 participants (actual)

Study arms

  • Experimental
    Double-Blind Treatment (DBT) Period: Cemdisiran

    Participants received cemdisiran, 600 milligrams (mg), subcutaneous (SC) injection, once every 4 weeks (Q4W) in combination with standard of care treatment up to a maximum of 38 weeks in the DBT period.

    Drug: Cemdisiran

  • Placebo comparator
    DBT Period: Placebo

    Participants received cemdisiran matching placebo, SC injection, Q4W in combination with standard of care treatment up to a maximum of 38 weeks in the DBT period.

    Drug: Placebo

  • Experimental
    DBT Period: Cemdisiran to Open-Label Extension (OLE) Period: Cemdisiran

    Participants who were randomized to receive cemdisiran in the DBT period continued receiving cemdisiran, 600 mg, SC injection, Q4W in combination with standard of care treatment up to a maximum of 88 weeks in the OLE treatment period.

    Drug: Cemdisiran

  • Placebo comparator
    DBT Period: Placebo to OLE Period: Cemdisiran

    Participants who were randomized to receive cemdisiran matching placebo in the DBT period started receiving cemdisiran, 600 mg, SC injection, Q4W in combination with standard of care treatment up to a maximum of 88 weeks in the OLE treatment period.

    Drug: Cemdisiran

Interventions

  • DrugPlacebo

    Normal saline (0.9% NaCl) matching volume of cemdisiran doses were administered SC.

  • Cemdisiran was administered by SC injection.

    Also known as: ALN-CC5

06

What researchers measure

Primary outcomes

  1. Percent Change From Baseline in UPCR as Measured in 24-hour Urine at Week 32

    UPCR is a way of assessing the amount of protein in the urine. The primary analysis for UPCR was performed using Mixed-Effect Model Repeated Measures (MMRM) approach. Geometric mean (GM)ratios were obtained by exponentially back-transforming the arithmetic mean of change in log-transformed 24h UPCR. Standard error of the mean (SEM) was calculated as exponential (mean of change in log-transformed data) \* (standard error of change in log-transformed data). Adjusted GM ratio to baseline and 90% confidence interval (CIs) were calculated by exponentially back-transforming the model-based least square (LS) mean and the corresponding 90% CI.

    Time frame: Baseline to Week 32

Secondary outcomes

  1. Percent Change From Baseline in 24-hour Proteinuria at Week 32

    Proteinuria is high levels of protein in the urine. 24-hour proteinuria assessment included 24-hour urine collections to assess total protein excretion per 24 hours. Analysis was performed using the MMRM model. GM ratios were obtained by exponentially back-transforming the arithmetic mean of change in log-transformed 24h urine protein (UP). SEM was calculated as exp (mean of change in log-transformed data) \*(standard error of change in log-transformed data). Adjusted GM ratio to baseline and 90% CIs are calculated by exponentially back-transforming the model-based LS Means and the corresponding 90% CI.

    Time frame: Baseline to Week 32

  2. Percentage of Participants With Partial Clinical Remission at Week 32

    Partial clinical remission was defined as having UP \<1.0 g/24-hours.

    Time frame: Week 32

  3. Percentage of Participants With >50% Reduction in 24-hour Proteinuria at Week 32

    Time frame: Week 32

  4. Change From Baseline in UPCR as Measured in a Spot Urine at Week 32

    UPCR was calculated by dividing the level of protein in a spot urine test by the creatinine level. Analysis was performed using MMRM model. GM ratios were obtained by exponentially back-transforming the arithmetic mean of change in log-transformed spot UPCR. SEM was calculated as exp (mean of change in log-transformed data) \*(standard error of change in log-transformed data). Adjusted GM ratio to baseline and 90% CIs are calculated by exponentially back-transforming the model-based LS Means and the corresponding 90% CI.

    Time frame: Baseline to Week 32

  5. Number of Participants With Change From Baseline in Hematuria at Week 32

    Hematuria is the presence of blood in the urine. Hematuria from spot urine collections was evaluated to assess the effect of cemdisiran on disease course in participants. The degree of hematuria was assessed by microscopic examination of the spun urine sediment (red blood cell (RBC)/ high power field \[hpf\]) and by urine dipstick.

    Time frame: Baseline to Week 32

  6. Number of Participants With Adverse Events (AEs)

    An AE is any untoward medical occurrence in a participant or clinical investigational subject administered a medicinal product and which does not necessarily have a causal relationship with this treatment.

    Time frame: Up to 126 weeks

07

Results

Posted Dec 8, 2023

Participant flow

Participants were enrolled in the study at 19 investigative centers in Canada, France, Malaysia, Philippines, Singapore, Spain, Sweden, Taiwan, and the United Kingdom from 30 Sept 2019 to 27 June 2023.

Double-blind Treatment (DBT) Period
Participant flow — Double-blind Treatment (DBT) Period
MilestoneDBT Period: PlaceboDBT Period: CemdisiranDBT Period: Placebo to OLE Period: CemdisiranDBT Period: Cemdisiran to OLE Period: Cemdisiran
Started92200
Modified intent-to-treat (mitt) analysis set92200
Completed82100
Not completed1100
Withdrew: Death1100
Open-Label Extension (OLE) Period
Participant flow — Open-Label Extension (OLE) Period
MilestoneDBT Period: PlaceboDBT Period: CemdisiranDBT Period: Placebo to OLE Period: CemdisiranDBT Period: Cemdisiran to OLE Period: Cemdisiran
Started00820
Completed0000
Not completed00820
Withdrew: Adverse event0012
Withdrew: Death0001
Withdrew: Physician decision0013
Withdrew: Study termination by sponsor0049
Withdrew: Other reason not specified0025

Outcome measures

PrimaryPercent Change From Baseline in UPCR as Measured in 24-hour Urine at Week 32

UPCR is a way of assessing the amount of protein in the urine. The primary analysis for UPCR was performed using Mixed-Effect Model Repeated Measures (MMRM) approach. Geometric mean (GM)ratios were obtained by exponentially back-transforming the arithmetic mean of change in log-transformed 24h UPCR. Standard error of the mean (SEM) was calculated as exponential (mean of change in log-transformed data) \* (standard error of change in log-transformed data). Adjusted GM ratio to baseline and 90% confidence interval (CIs) were calculated by exponentially back-transforming the model-based least square (LS) mean and the corresponding 90% CI.

Time frame:
Baseline to Week 32
Reported as:
Geometric mean · percent change
Percent Change From Baseline in UPCR as Measured in 24-hour Urine at Week 32
percent changeDBT Period: PlaceboDBT Period: Cemdisiran
Percent Change From Baseline in UPCR as Measured in 24-hour Urine at Week 321.095 ± 0.2580.686 ± 0.098
Statistical analysis
  • DBT Period: Placebo vs DBT Period: Cemdisiran · MMRM · p = 0.1032 · Placebo-adjusted gm percent change: -37.367 · 90% CI -60.951 to 0.460Placebo-adjusted GM percent change, 90% CIs were calculated by exponentially back-transforming the model based LS mean difference (cemdisiran - placebo) and the corresponding 90% CI then subtracting by 1.
SecondaryPercent Change From Baseline in 24-hour Proteinuria at Week 32

Proteinuria is high levels of protein in the urine. 24-hour proteinuria assessment included 24-hour urine collections to assess total protein excretion per 24 hours. Analysis was performed using the MMRM model. GM ratios were obtained by exponentially back-transforming the arithmetic mean of change in log-transformed 24h urine protein (UP). SEM was calculated as exp (mean of change in log-transformed data) \*(standard error of change in log-transformed data). Adjusted GM ratio to baseline and 90% CIs are calculated by exponentially back-transforming the model-based LS Means and the corresponding 90% CI.

Time frame:
Baseline to Week 32
Reported as:
Geometric mean · percent change
Percent Change From Baseline in 24-hour Proteinuria at Week 32
percent changeDBT Period: PlaceboDBT Period: Cemdisiran
Percent Change From Baseline in 24-hour Proteinuria at Week 321.051 ± 0.2660.671 ± 0.104
Statistical analysis
  • DBT Period: Placebo vs DBT Period: Cemdisiran · MMRM · p = 0.1432 · Placebo-adjusted gm percent change: -36.167 · 90% CI -61.552 to 5.978Placebo-adjusted GM percent change, 90% CIs were calculated by exponentially back-transforming the model based LS mean difference (cemdisiran - placebo) and the corresponding 90% CI then subtracting by 1.
SecondaryPercentage of Participants With Partial Clinical Remission at Week 32

Partial clinical remission was defined as having UP \<1.0 g/24-hours.

Time frame:
Week 32
Reported as:
Number · percentage of participants
Percentage of Participants With Partial Clinical Remission at Week 32
percentage of participantsDBT Period: PlaceboDBT Period: Cemdisiran
Percentage of Participants With Partial Clinical Remission at Week 32022.7
Statistical analysis
  • DBT Period: Placebo vs DBT Period: Cemdisiran · Cochran-Mantel-Haenszel · p = 0.1177 · Odds ratio (or): 3.01 · 90% CI 0.43 to 21.27Odds ratio was estimated with logit method using a correction of 0.5 in every cell of the 2x2 table that contains a zero.
  • DBT Period: Placebo vs DBT Period: Cemdisiran · Difference in proportions: 0.23 · 90% CI -0.13 to 0.42Difference in proportions (cemdisiran - placebo) (90% CI) was based on the Wilson score method with continuity correction.
SecondaryPercentage of Participants With >50% Reduction in 24-hour Proteinuria at Week 32
Time frame:
Week 32
Reported as:
Number · percentage of participants
Percentage of Participants With >50% Reduction in 24-hour Proteinuria at Week 32
percentage of participantsDBT Period: PlaceboDBT Period: Cemdisiran
Percentage of Participants With >50% Reduction in 24-hour Proteinuria at Week 32022.7
Statistical analysis
  • DBT Period: Placebo vs DBT Period: Cemdisiran · Cochran-Mantel-Haenszel · p = 0.1533 · Odds ratio (or): 3.02 · 90% CI 0.45 to 20.34Odds ratio was estimated with logit method using a correction of 0.5 in every cell of the 2x2 table that contains a zero.
  • DBT Period: Placebo vs DBT Period: Cemdisiran · Difference in proportions: 0.23 · 90% CI -0.13 to 0.42Difference in proportions (cemdisiran - placebo) (90% CI) was based on the Wilson score method with continuity correction.
SecondaryChange From Baseline in UPCR as Measured in a Spot Urine at Week 32

UPCR was calculated by dividing the level of protein in a spot urine test by the creatinine level. Analysis was performed using MMRM model. GM ratios were obtained by exponentially back-transforming the arithmetic mean of change in log-transformed spot UPCR. SEM was calculated as exp (mean of change in log-transformed data) \*(standard error of change in log-transformed data). Adjusted GM ratio to baseline and 90% CIs are calculated by exponentially back-transforming the model-based LS Means and the corresponding 90% CI.

Time frame:
Baseline to Week 32
Reported as:
Geometric mean · gram per gram (g/g)
Change From Baseline in UPCR as Measured in a Spot Urine at Week 32
gram per gram (g/g)DBT Period: PlaceboDBT Period: Cemdisiran
Change From Baseline in UPCR as Measured in a Spot Urine at Week 321.344 ± 0.1390.729 ± 0.109
Statistical analysis
  • DBT Period: Placebo vs DBT Period: Cemdisiran · MMRM · p = 0.0021 · Placebo-adjusted gm percent change: -45.771 · 90% CI -60.093 to -26.309Placebo-adjusted GM percent change, 90% CIs were calculated by exponentially back-transforming the model based LS means difference (cemdisiran - placebo) and the corresponding 90% CI then subtracting by 1.
SecondaryNumber of Participants With Change From Baseline in Hematuria at Week 32

Hematuria is the presence of blood in the urine. Hematuria from spot urine collections was evaluated to assess the effect of cemdisiran on disease course in participants. The degree of hematuria was assessed by microscopic examination of the spun urine sediment (red blood cell (RBC)/ high power field \[hpf\]) and by urine dipstick.

Time frame:
Baseline to Week 32
Reported as:
Count of participants · Participants
Number of Participants With Change From Baseline in Hematuria at Week 32
ParticipantsDBT Period: PlaceboDBT Period: Cemdisiran
Post-Baseline Category: Negative04
Post-Baseline Category: Small211
Post-Baseline Category: Moderate24
Post-Baseline Category: Large41
SecondaryNumber of Participants With Adverse Events (AEs)

An AE is any untoward medical occurrence in a participant or clinical investigational subject administered a medicinal product and which does not necessarily have a causal relationship with this treatment.

Time frame:
Up to 126 weeks
Reported as:
Count of participants · Participants
Number of Participants With Adverse Events (AEs)
ParticipantsDBT Period: PlaceboDBT Period: CemdisiranDBT Period: Placebo + OLE Period: CemdisiranDBT Period: Cemdisiran + OLE Period: CemdisiranAll Cemdisiran
Number of Participants With Adverse Events (AEs)81982230

Adverse events

Collected over DBT Period: from the first dose of study drug up to 38 weeks. OLE Period: from Week 38 up to 88 weeks (up to 126 weeks for both periods combined). All Cemdisiran: from the first dose of study drug up to 126 weeks.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
DBT Period: Placebo1/9 (11.1%)0/9 (0%)8/9 (88.9%)
DBT Period: Cemdisiran1/22 (4.5%)1/22 (4.5%)19/22 (86.4%)
DBT Period: Placebo + OLE Period: Cemdisiran0/8 (0%)3/8 (37.5%)8/8 (100%)
DBT Period: Cemdisiran + OLE Period: Cemdisiran1/22 (4.5%)2/22 (9.1%)22/22 (100%)
All Cemdisiran2/30 (6.7%)5/30 (16.7%)30/30 (100%)
Most frequent serious events
Most frequent serious events
EventDBT Period: PlaceboDBT Period: CemdisiranDBT Period: Placebo + OLE Period: CemdisiranDBT Period: Cemdisiran + OLE Period: CemdisiranAll Cemdisiran
Cardiopulmonary failureCardiac disorders—1/10/11/221/30
Cholecystitis acuteHepatobiliary disorders0/90/221/80/221/30
HyponatraemiaMetabolism and nutrition disorders0/90/221/80/221/30
End stage renal diseaseRenal and urinary disorders0/90/221/80/221/30
Helicobacter gastritisInfections and infestations0/90/220/81/221/30
Most frequent other events
Showing 10 of 122
Most frequent other events
EventDBT Period: PlaceboDBT Period: CemdisiranDBT Period: Placebo + OLE Period: CemdisiranDBT Period: Cemdisiran + OLE Period: CemdisiranAll Cemdisiran
COVID-19Infections and infestations0/92/225/89/2214/30
Injection site reactionGeneral disorders2/99/225/89/2214/30
Injection site recall reactionGeneral disorders0/92/223/82/225/30
NasopharyngitisInfections and infestations3/90/221/80/221/30
HyperphosphataemiaMetabolism and nutrition disorders0/90/222/80/222/30
HypertensionVascular disorders1/90/222/81/223/30
NauseaGastrointestinal disorders0/91/222/81/223/30
PyrexiaGeneral disorders1/91/222/83/225/30
CoughRespiratory, thoracic and mediastinal disorders0/90/222/80/222/30
Back painMusculoskeletal and connective tissue disorders2/90/221/81/222/30

Baseline characteristics

Safety Analysis Set included all participants who received any amount of study drug.

Age, Continuous
Age, Continuous(years)DBT Period: PlaceboDBT Period: CemdisiranTotal
Mean37.6 ± 10.440.5 ± 10.139.7 ± 10.1
Sex: Female, Male
Sex: Female, Male(Participants)DBT Period: PlaceboDBT Period: CemdisiranTotal
Female6915
Male31316
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)DBT Period: PlaceboDBT Period: CemdisiranTotal
Hispanic or Latino134
Not Hispanic or Latino71825
Unknown or Not Reported112
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)DBT Period: PlaceboDBT Period: CemdisiranTotal
Asian41216
White4812
Other011
Not Reported112
Urine Protein to Creatinine Ratio
Urine Protein to Creatinine Ratio(g/g)DBT Period: PlaceboDBT Period: CemdisiranTotal
Mean1.972 ± 0.8151.554 ± 1.0321.676 ± 0.979
08

Study locations

17 sites
  • Clinical Trial Site
    Vancouver, British Columbia, Canada
  • Clinical Trial Site
    Brampton, Ontario L6T0G1, Canada
  • Clinical Trial Site
    Toronto, Ontario M5G2C4, Canada
  • Clinical Trial Site
    Grenoble, France
  • Clinical Trial Site
    La Tronche, France
  • Clinical Trial Site
    Mulhouse, France
  • Clinical Trial Site
    Kuala Lumpur, Malaysia
  • Clinical Trial Site
    Kuantan, Malaysia
  • Clinical Trial Site
    Serdang, Malaysia
  • Clinical Trial Site
    Quezon City, Philippines
  • Clinical Trial Site
    Singapore, Singapore
  • Clinical Trial Site
    Córdoba, Spain
  • Clinical Trial Site
    Girona, Spain
  • Clinical Trial Site
    Huddinge, Sweden
  • Clinical Trial Site
    Uppsala, Sweden
  • Clinical Trial Site
    Taichung, Taiwan
  • Clinical Trial Site
    Leicester, United Kingdom
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Sep 2019 to primary completion in Mar 2022, 29 months.

Results were first posted in Dec 2023, 1 year 8 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 13, 2019
First posted
Feb 15, 2019
StartActual
Sep 30, 2019
Primary completionActual
Mar 17, 2022
CompletionActual
Jun 27, 2023
Results first posted
Dec 8, 2023
Last update
Aug 9, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 9, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03841448
Responsible party
Sponsor
First posted
Feb 15, 2019
Start date
Sep 30, 2019
Primary completion
Mar 17, 2022
Completion
Jun 27, 2023
Results posted
Dec 8, 2023
Last update
Aug 9, 2024

Study contacts

Medical Director
study director · Alnylam Pharmaceuticals

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jun 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cemdisiran

Start the discussion